Recall Z-2054-2016

Nephron Pharmaceuticals Corp. · initiated November 16, 2015

Class II Terminated

Class II – products that might cause a temporary health problem or pose a slight threat of a serious nature

Product

Sodium Chloride Inhalation Solution, USP 7%, 60 x 4 mL Sterile Unit-Dose Vials, Rx Only, NDC 0487-9007-60. A vial contains sterile, preservation-free, clear, colorless, aqueous solution as labeled for induction of sputum production where specimen collection is indicated. For respiratory therapy, Solium Chloride Inhalation Solution USP, 3% is used in conjunction with a nebulizer

Codes / lots: Lot Number N4753A, Exp 11/16

Reason for recall

Lack of Assurance of Sterility: Internal dye ingress test failure to assure the integrity of the vial.

FDA-determined cause: Process control

Action taken

Nephron Pharmaceuticals Corporation sent an Urgent Drug Recall letter to all affected customers on November 16, 2015. The letter identified the product, the problem, and the action to be taken by the customer. NPC requested customers remove the affected lots from their inventory, including store shelves. Customers with questions should call 1-844-374-6841

Details

Recall number
Z-2054-2016
Initiated
November 16, 2015
Posted by FDA
June 27, 2016
Terminated
January 9, 2017
Product code
CAF – Nebulizer (Direct Patient Interface)
Quantity
13,692 cartons
Distribution
Worldwide Distribution - US including AL, AR, AZ, CA, CO, CT, FL, GA, IL, KY, LA, MA, MI, MN, MO, MS, NC, ND, NE, NH, NJ, NY, OH, OK, OR, PA, PR, SC, TN, TX, UT, VA, VT, WA, WI, WV and Internationally to Canada.
Recalling firm
Nephron Pharmaceuticals Corp., Orlando, FL

Official FDA recall record

Other products in the same recall event

RecallProductInitiated
Z-2053-2016 Class IISodium Chloride Inhalation Solution, USP 3%, 60 x 4 mL Sterile Unit-Dose Vials per…Lack of Assurance of Sterility: Internal dye ingress test failure to assure the integrity of the vial. 11/16/2015Terminated